相关实验视频

Updated: May 22, 2025

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

没有证据表明,在COPD和慢性支气管炎患者的恶化期间,有额外的系统性乙氨基细胞动员,但没有过敏症

Anders Andersson^1,2, Kristina Andelid^1,2, Bettina Brundin³

¹COPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Frontiers in medicine

|May 20, 2025

概括

在患有慢性肺炎和慢性支气管炎但没有过敏的患者中,在恶化期间,血中乙氨基酸水平不会增加. 这表明,向全身性乙氨基酸可能无法有效地预防这种患者群体的恶化.

科学领域:

肺部医学肺部医学
免疫学免疫学免疫学
呼吸系统研究呼吸系统研究

背景情况:

稳定性慢性肺炎患者血中乙氨基酸的升高与恶化风险和吸入性皮质类固醇的潜在益处相关.
之前的研究表明,针对COPD恶化预防的系统性乙氨基基细胞动员.
在非过敏性COPD患者的恶化期间缺乏系统性乙氨基基基动员的数据.

研究的目的:

在没有过敏的COPD患者中,研究稳定疾病和恶化期间的全身氨酸细胞动员.
为了比较COPD患者,长期吸烟者和健康个体的乙氨基酸,乙氨基酸蛋白 (ECP) 和介质蛋白-4 (IL-4) 水平.

主要方法:

横截面和纵向研究设计.
包括患有COPD和慢性支气管炎的长期吸烟者 (COPD-CB; n=47),没有COPD的长期吸烟者 (LTS; n=10) 和健康的从未吸烟者 (HNS; n=10).
在稳定疾病和恶化期间 (不包括皮质类固醇使用) 测量血液中乙酸氨基基基,ECP和IL-4.

主要成果:

在病情稳定期间,在COPD-CB和LTS组中,乙氨基基基度相似,高于HNS.
在COPD-CB和LTS组之间,ECP和IL-4度是可比的.
恶化并没有导致乙素,ECP或IL-4的增加;观察到下降的趋势.

结论:

在慢性支气管炎的非过敏性COPD患者的恶化期间,系统性乙氨基基基动员似乎不会增加.
在这种COPD表型中向全身乙氨基酸的免疫学理由需要进一步研究.
未来的研究应该根据过敏和慢性支气管炎的状态对大队列进行分层,以验证.

关键词:

慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性慢性肺炎.在 ECP ECP 中,您可以使用 ECP.IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL is is is is is what is what is what is what is what is what is what is 生物标志物生物标志物恶化的恶化.一个系统性的系统.

更多相关视频

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

相关概念视频

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.